{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:40:47Z","timestamp":1791088847097,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":1431,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1097\/jto.0b013e31822eebf9","type":"journal-article","created":{"date-parts":[[2011,10,19]],"date-time":"2011-10-19T04:23:39Z","timestamp":1318998219000},"page":"219-226","source":"Crossref","is-referenced-by-count":41,"title":["XL647\u2014A Multitargeted Tyrosine Kinase Inhibitor: Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding to Treatment with Either Gefitinib or Erlotinib"],"prefix":"10.1016","volume":"7","author":[{"given":"M. Catherine","family":"Pietanza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Thomas James","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Primo N.","family":"Lara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald H.","family":"Yanagihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandagopal","family":"Vrindavanam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed Mahfooz","family":"Chowhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirish M.","family":"Gadgeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan A.","family":"Pennell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roel","family":"Funke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather A.","family":"Wakelee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent A.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e31822eebf9_bib1","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1097\/JTO.0b013e31822eebf9_bib2","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1097\/JTO.0b013e31822eebf9_bib3","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e31822eebf9_bib4","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e31822eebf9_bib5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1097\/JTO.0b013e31822eebf9_bib6","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1097\/JTO.0b013e31822eebf9_bib7","doi-asserted-by":"crossref","first-page":"6494","DOI":"10.1158\/1078-0432.CCR-06-1570","article-title":"Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors","volume":"12","author":"Balak","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e31822eebf9_bib8","doi-asserted-by":"crossref","first-page":"20932","DOI":"10.1073\/pnas.0710370104","article-title":"MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib","volume":"104","author":"Bean","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1097\/JTO.0b013e31822eebf9_bib9","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"10.1097\/JTO.0b013e31822eebf9_bib10","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e31822eebf9_bib11","doi-asserted-by":"crossref","first-page":"7665","DOI":"10.1073\/pnas.0502860102","article-title":"Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib","volume":"102","author":"Kwak","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1097\/JTO.0b013e31822eebf9_bib12","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med"},{"key":"10.1097\/JTO.0b013e31822eebf9_bib13","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1158\/1078-0432.CCR-10-2692","article-title":"Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation","volume":"17","author":"Oxnard","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e31822eebf9_bib14","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1158\/1078-0432.CCR-06-2590","article-title":"Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647","volume":"13","author":"Gendreau","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e31822eebf9_bib15","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.8053","article-title":"Activity of XL647 in clinically selected NSCLC patients enriched for the presence of EGFR mutations: results from phase 2","volume":"26","author":"Rizvi","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31822eebf9_bib16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1097\/JTO.0b013e31822eebf9_bib17","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.3528","article-title":"A phase I study of XL647, an EGFR, HER2, VEGFR2 inhibitor, administered orally daily to patients with advanced solid malignancies","volume":"26","author":"Wakelee","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31822eebf9_bib18","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1200\/JCO.2005.08.043","article-title":"EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment","volume":"23","author":"Marchetti","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31822eebf9_bib19","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1525-1578(10)60569-7","article-title":"Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas","volume":"7","author":"Pan","year":"2005","journal-title":"J Mol Diagn"},{"key":"10.1097\/JTO.0b013e31822eebf9_bib20","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1158\/1078-0432.CCR-05-2324","article-title":"Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer","volume":"12","author":"Kimura","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e31822eebf9_bib21","doi-asserted-by":"crossref","first-page":"4954","DOI":"10.1158\/1078-0432.CCR-07-1387","article-title":"Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method","volume":"13","author":"Pao","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e31822eebf9_bib22","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nm1437","article-title":"Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing","volume":"12","author":"Thomas","year":"2006","journal-title":"Nat Med"},{"key":"10.1097\/JTO.0b013e31822eebf9_bib23","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1158\/1078-0432.CCR-07-0560","article-title":"Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus","volume":"13","author":"Riely","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e31822eebf9_bib24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3727\/096504005775082020","article-title":"Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases","volume":"15","author":"Yano","year":"2005","journal-title":"Oncol Res"},{"key":"10.1097\/JTO.0b013e31822eebf9_bib25","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/ncponc0400","article-title":"Gefitinib response of erlotinib-refractory lung cancer involving meninges\u2014role of EGFR mutation","volume":"3","author":"Choong","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1097\/JTO.0b013e31822eebf9_bib26","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/annonc\/mdh006","article-title":"Effect of re-treatment with gefitinib (\u2018Iressa,' ZD1839) after acquisition of resistance","volume":"15","author":"Kurata","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1097\/JTO.0b013e31822eebf9_bib27","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1200\/JCO.2009.24.7049","article-title":"Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer","volume":"28","author":"Jackman","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31822eebf9_bib28","doi-asserted-by":"crossref","unstructured":"Chmielecki J, Pietanza MC, Kris MG, et al. EGFR mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib. J Thoracic Oncol. In press.","DOI":"10.1097\/JTO.0b013e31823c5aee"},{"key":"10.1097\/JTO.0b013e31822eebf9_bib29","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1056\/NEJMoa0800668","article-title":"Detection of mutations in EGFR in circulating lung-cancer cells","volume":"359","author":"Maheswaran","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e31822eebf9_bib30","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/ijc.24653","article-title":"Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer","volume":"125","author":"He","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1097\/JTO.0b013e31822eebf9_bib31","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1158\/1078-0432.CCR-08-2622","article-title":"Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients","volume":"15","author":"Yung","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e31822eebf9_bib32","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1158\/1078-0432.CCR-08-2592","article-title":"Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer","volume":"15","author":"Kuang","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e31822eebf9_bib33","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1200\/JCO.2009.27.9414","article-title":"Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer","volume":"28","author":"Sequist","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31822eebf9_bib34","unstructured":"Miller VA, Hirsh V, Cadranel J, et al. Phase IIb\/III Trial Of Afatinib (BIBW 2992) And Best Supportive Care Vs. Placebo and Best Supportive Care in Patients Failing 1 to 2 Lines of Chemotherapy and Erlotinib\/Gefitinib (LUX-Lung 1). In: ESMO; 2010. Milan, Italy: Annals of Oncology, 2010. LBA 1."},{"key":"10.1097\/JTO.0b013e31822eebf9_bib35","first-page":"S557","article-title":"Subgroup analysis of lux-lung 1: a randomized phase III trial of afatinib (BIBW2992) and best supportive care versus placebo and best supportive care in patients with NSCLC failing 1 to 2 lines of chemotherapy and erlotinib or gefitinib","volume":"5","author":"Miller","year":"2010","journal-title":"J Thorac Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415317810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415317810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T23:10:11Z","timestamp":1560813011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415317810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S1556086415317810"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e31822eebf9","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}